SCHEMBL3428346

SCHEMBL3428346

C[C@H](Oc1cccc(NC(N)=S)c1)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.49
CYP1A2 P05177 1/20 0.49
TSHR P16473 2/20 0.49
TP53 P04637 1/20 0.49
TYR P14679 1/20 0.49
TAS2R38 P59533 1/20 0.49
HSD17B10 Q99714 1/20 0.49
LMNA P02545 3/20 0.47
ALOX12 P18054 3/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
KMT2A Q03164 5/20 0.46
MEN1 O00255 4/20 0.46
MAPT P10636 3/20 0.46
HTT P42858 2/20 0.46
ALPL P05186 1/20 0.46
RORC P51449 2/20 0.46
NPY5R Q15761 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3424219 1.00 ALDH1A1 (0.49) ALDH1A1CYP1A2TSHRTP53TYR
SCHEMBL11128200 0.82 TSHR (0.56) ALDH1A1CYP1A2TSHRNPC1RAB9A
SCHEMBL7900721 0.78 ALOX5 (0.51) ALDH1A1LMNAALOX12NPC1RAB9A
SCHEMBL3425886 0.77 ALDH1A1 (0.60) ALDH1A1CYP1A2TSHRTP53TYR
SCHEMBL27775984 0.77 ALDH1A1 (0.46) ALDH1A1CYP1A2TSHRTP53TYR
SCHEMBL4373590 0.77 NPC1 (0.63) ALDH1A1TSHRTP53LMNAALOX12
SCHEMBL4366045 0.77 NPC1 (0.63) ALDH1A1TSHRTP53LMNAALOX12
SCHEMBL4366238 0.76 ALDH1A1 (0.64) ALDH1A1LMNAALOX12NPC1RAB9A
SCHEMBL4365221 0.76 ALDH1A1 (0.52) ALDH1A1CYP1A2TSHRLMNAALOX12
SCHEMBL4539373 0.76 ALDH1A1 (0.64) ALDH1A1LMNAALOX12NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7718671-B2 Substituted arylthiourea derivatives useful as inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2010-05-18 US claimed
US-20050032849-A1 Substituted arylthiourea derivatives useful as inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. 2005-02-10 US claimed
US-7718671-B2 Substituted arylthiourea derivatives useful as inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2010-05-18 US disclosed
US-7718671-B2 Substituted arylthiourea derivatives useful as inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2010-05-18 US disclosed
US-7718671-B2 Substituted arylthiourea derivatives useful as inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2010-05-18 US disclosed
US-20050032849-A1 Substituted arylthiourea derivatives useful as inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. 2005-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032849-A1 Substituted arylthiourea derivatives useful as inhibitors of viral replication TPMT, NAT1, GOT1 ALDH1A1 261/4885CYP1A2 556/4885TSHR 1922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.